Peer-reviewed veterinary case report
Stereotactic radiation treatment for dogs with bone tumors
By Sweet, Katherine A et al.·Published in Veterinary and comparative oncology·2020·Department of Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Stereotactic radiation therapy for canine multilobular osteochondrosarcoma: Eight cases.
- Species:
- dog
Plain-English summary
An 8-year-old mixed-breed dog was diagnosed with a type of bone cancer called multilobular osteochondrosarcoma (MLO) and showed symptoms like a noticeable mass, breathing difficulties, and changes in behavior. The dog received stereotactic radiation therapy, which involved three days of targeted radiation treatment. After the therapy, four out of five dogs that had follow-up scans showed a significant reduction in tumor size, while one dog’s tumor grew. Although the treatment was generally well-tolerated, some dogs experienced mild to moderate side effects, and the overall survival time was about 10 months.
People also search for: dog bone cancer treatment · stereotactic radiation therapy for dogs · multilobular osteochondrosarcoma in dogs · dog tumor symptoms · dog cancer survival rates
Abstract
Radiotherapy is often considered in the management of canine multilobular osteochondrosarcoma (MLO), but its efficacy against bulky MLO tumours is poorly described. This retrospective case series describes the clinical outcomes of pet dogs with MLO treated with a stereotactic radiation therapy (SRT) prescription of 30 Gy in three consecutive daily 10 Gy fractions. Dogs with an imaging (via computed tomography [CT] scan) and/or pathologic diagnosis of MLO were included. Patient demographics, tumour characteristics, radiation plan dosimetry, toxicity and outcome data were obtained retrospectively from the records. The median progression-free survival time (MPFST) and median overall survival time (MST) were calculated using a LOGLOG test. Eight dogs were included. None had evidence of metastasis at the time of SRT. Clinical signs associated with the MLO included a mass noted by owner, stertor, vestibular signs, exophthalmos and abnormal mentation. Of the five dogs that had CT scans performed 3 to 9 months after SRT, tumour volume decreased by 26% to 87% in four dogs and increased by 32% in one dog. Late radiation toxicity was documented in three dogs (VRTOG Grade 1 skin and/or ocular, n = 2; Grade 3 central nervous system, n = 1). Confirmed local disease progression (n = 3; two were treated with a second course of SRT) and suspected pulmonary metastasis (n = 2) occurred 90 to 315 days after SRT. The MPFST was 223 days (interquartile range [IQR]: 144.5-276.5 days). The MST was 329 days (IQR: 241.5-408 days). This protocol was well-tolerated, but the duration of response was short-lived.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30989784/